The Coronavirus Disease 2019 pandemic, caused by the severe acute respiratory syndrome-associated coronavirus (SARS-CoV-2), is having devastating effects on every country around the world. SARS-CoV-2 can be fatal in patients with described risk factors. A question remains as to whether other immunosuppressed populations are at risk for severe complications. There is limited data on the impact of COVID-19 in young patients with bone marrow failure syndromes (BMFs). 29 institutions, from the NAPAAC consortium, reported 4 with BMFs diagnosed with SARS-CoV-2. These patients presented with relatively mild clinical courses, raising questions as to why this apparently low morbidity and mortality

Increasing availability of genomic testing poses new challenges to clinicians, particularly where variant interpretation from commercial sources may be equivocal. We report a patient with recurrent rhabdomyosarcoma and subsequent bilateral breast cancer who was found to harbor a previously undescribed germline TP53 sequence alteration annotated by the commercial laboratory as a variant of uncertain significance (VUS). By investigating publically available databases of aggregated normal germline and malignant somatic genomic sequences, we conclude that this missense variant, c.476C>T (p.A159V), is a novel, pathogenic Li-Fraumeni syndrome mutation, and illustrate the utility of these resources in clinical pediatric hematology and oncology practice.